Fries, Anissa
Saidoune, Fanny
Kuonen, François http://orcid.org/0000-0001-6137-7483
Dupanloup, Isabelle
Fournier, Nadine http://orcid.org/0000-0002-9347-7929
Guerra de Souza, Ana Cristina
Haniffa, Muzlifah
Ma, Feiyang http://orcid.org/0000-0002-6260-0787
Gudjonsson, Johann E. http://orcid.org/0000-0002-0080-0812
Roesner, Lennart http://orcid.org/0000-0001-6651-0458
Li, Yang http://orcid.org/0000-0003-4022-7341
Werfel, Thomas
Conrad, Curdin http://orcid.org/0000-0002-2547-3440
Gottardo, Raphael
Modlin, Robert L. http://orcid.org/0000-0003-4720-031X
Di Domizio, Jeremy http://orcid.org/0000-0002-6281-3918
Gilliet, Michel http://orcid.org/0000-0002-4609-3762
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030B_182834, 310030_204835)
DH | National Institute for Health Research (P30-AR075043, R01-AR080594)
Deutsche Forschungsgemeinschaft (EXC 2155 “RESIST”—Project ID 390874280)
Article History
Received: 24 January 2023
Accepted: 15 June 2023
First Online: 30 June 2023
Competing interests
: J.D.D. and M.G. are inventors of a patent entitled “IL-26 inhibitors” (WO2017009392A1). R.G. declares ownership in Ozette Technologies. The remaining authors declare no competing interests.